Phenotypic screens for compounds that target the cellular pathologies underlying Parkinson's disease

Drug Discovery Today: Technologies

Volumn 10, Issue 1, 2013, Pages

  Tardiff, Daniel F ^a   Lindquist, Susan ^a,b  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; OXIDOPAMINE; ROTENONE; STROPHANTHIDIN;

5' UNTRANSLATED REGION; CAENORHABDITIS ELEGANS; CELL CULTURE; CELL MEMBRANE PERMEABILITY; CYTOTOXICITY; DISEASE COURSE; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; GENE OVEREXPRESSION; GENETIC MODEL; HIGH THROUGHPUT SCREENING; HUMAN; IN VIVO STUDY; LICENSING; NEUROBLASTOMA CELL; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; REVIEW; SACCHAROMYCES CEREVISIAE; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PARKINSON DISEASE; PHENOTYPE; YEASTS;

EID: 84875724418     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.02.003     Document Type: Review

References (49)

1. M.G. Spillantini Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
2. M.H. Polymeropoulos Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 1997 2045 2047
3. A.B. Singleton Alpha-Synuclein locus triplication causes Parkinson's disease Science 302 2003 841
4. W. Li Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation J. Neurosci. 24 2004 7400 7409
5. Y. Chu, and J.H. Kordower Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol. Dis. 25 2007 134 149
6. I. Martin Recent advances in the genetics of Parkinson's disease Annu. Rev. Genomics Hum. Genet. 12 2011 301 325
7. S. Hisahara, and S. Shimohama Toxin-induced and genetic animal models of Parkinson's disease Parkinsons Dis. 2011 2010 951709
8. T.M. Dawson Genetic animal models of Parkinson's disease Neuron 66 2010 646 661
9. W.G. Meissner Priorities in Parkinson's disease research Nat. Rev. Drug Discov. 10 2011 377 393
10. D.C. Swinney, and J. Anthony How were new medicines discovered? Nat. Rev. Drug Discov. 10 2011 507 519
11. T.F. Outeiro Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease Science 317 2007 516 519
12. D.L. Zhao A cell-based model of alpha-synucleinopathy for screening compounds with therapeutic potential of Parkinson's disease Acta Pharmacol. Sin. 28 2007 616 626
13. P.J. McLean Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro Biochem. Biophys. Res. Commun. 321 2004 665 669
14. P. Putcha Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity J. Pharmacol. Exp. Ther. 332 2010 849 857
15. T.F. Outeiro Formation of toxic oligomeric alpha-synuclein species in living cells PLoS ONE 3 2008 e1867
16. R.A. Bodner Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases Proc. Natl. Acad. Sci. U.S.A. 103 2006 4246 4251
17. P.K. Auluck, and N.M. Bonini Pharmacological prevention of Parkinson disease in Drosophila Nat. Med. 8 2002 1185 1186
18. T.F. Outeiro, and S. Lindquist Yeast cells provide insight into alpha-synuclein biology and pathobiology Science 302 2003 1772 1775
19. A.L. Friedlich The 5′-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element Mol. Psychiatry 12 2007 222 223
20. Ross NT, et al. (2011) Identification of a small molecule that selectively activates alpha-synuclein translational expression. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). (Updated 2011 Feb 15)
21. Ross NT, et al. (2011) Identification of a small molecule that selectively inhibits alpha-synuclein translational expression. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). (Updated 2011 Feb 15)
22. J.T. Rogers The alpha-synuclein 5′-untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen J. Neural Transm. 118 2011 493 507
23. I.S. Yoon Development of a high-throughput screening assay for cytoprotective agents in rotenone-induced cell death Anal. Biochem. 407 2010 205 210
24. V.C. Abraham High content screening applied to large-scale cell biology Trends Biotechnol. 22 2004 15 22
25. A.D. Gitler The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis Proc. Natl. Acad. Sci. U.S.A. 105 2008 145 150
26. A.A. Cooper Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models Science 313 2006 324 328
27. A.D. Gitler Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity Nat. Genet. 41 2009 308 315
28. L.J. Su Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models Dis. Model Mech. 3 2010 194 208
29. S. Hoon An integrated platform of genomic assays reveals small-molecule bioactivities Nat. Chem. Biol. 4 2008 498 506
30. G. Griffioen A yeast-based model of alpha-synucleinopathy identifies compounds with therapeutic potential Biochim. Biophys. Acta 1762 2006 312 318
31. C.P. Scott Production of cyclic peptides and proteins in vivo Proc. Natl. Acad. Sci. U.S.A. 96 1999 13638 13643
32. J.A. Kritzer Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models Nat. Chem. Biol. 5 2009 655 663
33. S. Sarkar Small molecules enhance autophagy and reduce toxicity in Huntington's disease models Nat. Chem. Biol. 3 2007 331 338
34. J. Huang Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips Proc. Natl. Acad. Sci. U.S.A. 101 2004 16594 16599
35. D.W. Neef Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease PLoS Biol. 8 2010 e1000291
36. P.K. Auluck Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease Science 295 2002 865 868
37. E. Yeger-Lotem Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity Nat. Genet. 41 2009 316 323
38. D.F. Tardiff Different 8-hydroxyquinolines protect models of TDP-43 protein, alpha-synuclein, and polyglutamine proteotoxicity through distinct mechanisms J. Biol. Chem. 287 2012 4107 4120
39. A.J. Harrington C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease Dev. Dyn. 239 2010 1282 1295
40. M. Marvanova, and C.D. Nichols Identification of neuroprotective compounds of caenorhabditis elegans dopaminergic neurons against 6-OHDA J. Mol. Neurosci. 31 2007 127 137
41. E. Braungart Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings Neurodegen. Dis. 1 2004 175 183
42. C. Samara Large-scale in vivo femtosecond laser neurosurgery screen reveals small-molecule enhancer of regeneration Proc. Natl. Acad. Sci. U.S.A. 107 2010 18342 18347
43. D. Paquet A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation J. Clin. Invest. 119 2009 1382 1395
44. T.V. Bowman, and L.I. Zon Swimming into the future of drug discovery: in vivo chemical screens in zebrafish ACS Chem. Biol. 5 2010 159 161
45. F. Soldner Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations Cell 146 2011 318 331
46. F. Soldner Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors Cell 136 2009 964 977
47. H.N. Nguyen LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress Cell Stem Cell 8 2011 267 280
48. M.J. Devine Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus Nat. Commun. 2 2011 440
49. B.H. Munos, and W.W. Chin How to revive breakthrough innovation in the pharmaceutical industry Sci. Transl. Med. 3 2011 89cm16